5 / 6
Journal of Clinical and Molecular Endocrinology
ISSN: 2572-5432
June 07-08, 2018
London, UK
PCOS 2018
Page 15
4
th
World Congress on
Polycystic Ovarian
Syndrome
Objective:
To determine the efficacy of sitagliptin alone or in
combination with metformin in women with polycystic ovary in
terms of ovarian cyclicity, fertility and cardiometabolic profile
compared to metformin alone.
Rationale:
Polycystic ovarian syndrome (PCOS) affects a
percentage of 5–10% of women of reproductive age worldwide
and has a prevalence of 6.6% (95% CI: 2.3–10.9%) in Mexican
women and most common cause of infertility in developed
countries. Treatment with insulin sensitizing drugs (metformin
and pioglitazone) has been shown to improvemenstrual cyclicity
and fertility in the metabolic profile with polycystic ovarian
patients. Incretins and DPP-4 inhibitors have been shown to
enhance pancreatic β cell activity, increasing weight loss by its
anorexic effect and resulting in an adequate weight control and
improved fertility. Previous evidence has compared the effect
of exenatide and alone or in combination with metformin in the
treatment of PCOS, in this article we will compare sitagliptin and
metformin alone or in combination.
Study design:
Blind, controlled and randomized clinical trial.
Patients:
Women between 18 and 40 years of age, with a BMI
>20 and diagnosed with PCOS with the Rotterdam criteria.
Results:
In the normalized index of menstruations it was found
that there was a statistically significant intragroup increase in
each one of the treatments. With a higher percentage of change,
that of metformin with 80%, followed by that of sitagliptin with
65% and then COMBO with 30%. No statistically significant
differences were found between treatment groups.
Conclusion:
Therapeutic effect of sitagliptin was observed
in patients with PCOS comparable to metformin and the
combination of metformin-sitagliptin is more effective in terms
of ovulation than the other two treatments alone.
Comparative treatment between sitagliptin vs.
metformin, alone or in combination, in patients
with polycystic ovary syndrome. A clinical entity
at high risk for developing diabetes mellitus and
gestational diabetes: A pilot study
J.C.Paredes Palma
a
, E.López Byhen
b
, L.Ibáñez
c
, L.Balladares
Macedo
d
, C.Paredes Palma
d
and
C.Ramírez Velázquez
a
a
Sub delegación sur ISSSTE, Mexico City, Mexico
b
Departamento de Toxicología, CINVESTAV, Mexico City, Mexico
c
Hospital General DR. Fernando Quiroz Gutiérrez ISSSTE, Mexico
d
Clínica de Cirugía Ginecológica Laparoscópica y Endoscópica, CE Churubusco ISSSTE
Mexico City, Mexico
J.C.Paredes Palma, J Clin Mol Endocrinol 2018, Volume 3
DOI: 10.21767/2572-5432-C1-001